Japanese study checks safety of gaucher drug VPRIV in Real-World use
NCT ID NCT03625882
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in Japan looked at the safety and effectiveness of the drug VPRIV (velaglucerase alfa) in 63 people with Gaucher disease. Participants were either new to treatment or switching from another Gaucher therapy. The main goal was to track side effects and serious side effects, while also measuring changes in hemoglobin levels. Because this is an observational survey, it helps confirm how the drug works in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
velaglucerase alfa (VPRIV)
What this could lead to
If results are positive, this could confirm that VPRIV is a safe and effective option for managing Gaucher disease in Japanese patients.
What could go wrong
This is an observational survey, not a controlled trial, so it cannot prove cause and effect. The small size (63 people) and single-country setting may limit how well the findings apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba
Chiba, 266-0007, Japan
-
Fukuyama
Fukuyama, Hiroshima, 721-0927, Japan
-
Gifu
Gifu, 500-8212, Japan
-
Hamamatsu
Hamamatsu, Shizuoka, 431-3125, Japan
-
Hamamatsu
Hamamatsu, Shizuoka, 434-8511, Japan
-
Higashihiroshima
Higashihiroshima, Hiroshima, 739-0041, Japan
-
Hiroshima
Hiroshima, 730-0046, Japan
-
Hiroshima
Hiroshima, 734-0037, Japan
-
Iwata
Iwata, Shizuoka, 438-0002, Japan
-
Kagoshima
Kagoshima, 892-0853, Japan
-
Kawagoe
Kawagoe, Saitama, 350-8550, Japan
-
Kitakyushu
Kitakyushu, Fukuoka, 802-0803, Japan
-
Konan
Kōnan, Aichi-ken, 483-8704, Japan
-
Kumamoto
Kumamoto, 860-8556, Japan
-
Kurume
Kurume, Fukuoka, 830-0011, Japan
-
Kyoto
Kyoto, 606-8507, Japan
-
Matsue
Matsue, Shimane, 690-0864, Japan
-
Minato
Minato, Tokyo, 105-8471, Japan
-
Moriyama
Moriyama, Shiga, 524-0022, Japan
-
Nagoya
Nagoya, Aichi-ken, 453-0801, Japan
-
Obihiro
Obihiro, Hokkaido, 080-0016, Japan
-
Okayama
Okayama, 701-1192, Japan
-
Osaka
Osaka, 534-0021, Japan
-
Osaka
Osaka, 545-8586, Japan
-
Osaka
Osaka, 553-0003, Japan
-
Otsu
Ōtsu, Shiga, 520-2192, Japan
-
Sagamihara
Sagamihara, Kanagawa, 252-0375, Japan
-
Saitama
Saitama, 339-8551, Japan
-
Sendai
Sendai, Miyagi, 980-8574, Japan
-
Shizuoka
Shizuoka, 420-8688, Japan
-
Suita
Suita, Osaka, 565-0871, Japan
-
Sumida-ku
Sumida-ku, Tokyo, 130-0005, Japan
-
Tokorozawa
Tokorozawa, Saitama, 359-8513, Japan
-
Tondabayashi
Tondabayashi, Osaka, 584-0000, Japan
-
Yonago
Yonago, Tottori, 683-8504, Japan